Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel in treating
women who have stage III breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Aventis Pharmaceuticals National Cancer Institute (NCI)